San Diego, California (UroToday.com): A very interesting poster was presented in today’s Prostate cancer: advanced session at the AUA 2016 evaluating PSMA-Targeted 18F-DCFPyL PET/CT in the Men with an Elevated PSA Following Radical Prostatectomy. Dr Michael A. Gorin reminded all that PET/CT) utilizing radiotracers targeting prostate-specific membrane antigen is a promising novel method for imaging low volume sites of prostate cancer.
The authors sought to evaluate the utility of PSMA-targeted18F-DCFPyL PET/CT in men with an elevated PSA following radical prostatectomy. The study enrolled prostate cancer patient who had radical prostatectomy and serum PSA levels of 0.2-1ng/ml. these patients were imaged with CT or MRI of the abdomen, bone scan and 18F-DCFPyL PET/CT. Sensitivity analysis was performed on and on the 18F-DCFPyL PET/CT compared with the conventional imaging modalities. 20 men were included in the study and were imaged as previously described. Only 4 patients were diagnosed with more than 1 site of disease with the conventional imaging modality. On the other hand, 13 patients were found to have more than 1 foci of abnormal radiotracer uptake on 18F-DCFPyL PET/CT. of these 13 patients, 7 had a local recurrence, 14 had lymph node metastases and 1 had bony disease. 18F-DCFPyL PET/CT identified all disease site that were detected by the conventional imaging modalities. The authors conclude that 18F-DCFPyL PET/CT is a sensitive test to diagnose disease sites in man after radical prostatectomy and biochemical failure.
Presented By: Michael A. Gorin, MD
Written By: Miki Haifler MD. Fox Chase Cancer Center, Philadelphia, PA. at the 2016 AUA Annual Meeting - May 6 - 10, 2016 – San Diego, California, USA